+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rabies Vaccine Market Size, Share & Trends Analysis Report By Prophylaxis Type (Post-exposure Prophylaxis, and Pre-exposure prophylaxis), By End User, By Application (Human, and Animal), By Product Type, By Regional Outlook and Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 250 Pages
  • March 2024
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5949644
The Global Rabies Vaccine Market size is expected to reach $1.6 billion by 2030, rising at a market growth of 4.5% CAGR during the forecast period.

Pet owners increasingly adopt preventive healthcare practices for their animals, mirroring trends in human healthcare. Regular veterinary visits, including vaccinations, are proactive measures to protect pets from diseases such as rabies, fostering a continuous demand for vaccines. Consequently, the Veterinary clinics segment would acquire nearly, 20% market share by 2030. Advancements in veterinary medicine, including the availability of improved and safer vaccines, contribute to a positive perception of vaccinations among pet owners.



Ongoing R&D activities focus on improving the formulation of these vaccines. Researchers work to enhance vaccine stability, reduce adverse reactions, and optimize the immune response. R&D efforts aim to develop next-generation vaccines with enhanced characteristics. This may include vaccines with longer-lasting immunity, novel delivery methods, and the ability to protect against a broader spectrum of rabies virus variants. Therefore, the market is expanding significantly due to the rising research and development (R&D) initiatives. Additionally, Rabies poses a severe threat to human health as it can be transmitted through the saliva of infected animals, primarily through bites or scratches. Zoonotic diseases often transcend national borders, necessitating global collaboration. Collaborative efforts and funding support facilitate the implementation of vaccination programs to control and eliminate rabies, particularly in regions where the disease poses a significant zoonotic threat. Hence, increasing awareness of zoonotic diseases like rabies has been a pivotal factor in driving the growth of the market.

Moreover, The COVID-19 pandemic disrupted routine healthcare services, including vaccination programs. Lockdowns, restrictions on movement, and healthcare system strain may affect the implementation of rabies vaccination campaigns, particularly in regions with limited resources. Travel restrictions and disruptions in global transportation may affected the movement of professionals involved in global health initiatives and collaborations. This impact global efforts to control and eliminate rabies. Thus, the COVID-19 pandemic had a moderate effect on the market.

However, High vaccination program costs can restrict access to these vaccines, particularly in resource-constrained areas. Governments responsible for public health initiatives may experience financial strain when implementing rabies vaccination programs. The allocation of resources to these programs may compete with other essential healthcare needs, potentially leading to budget constraints. Thus, high cost can slow down the growth of the market.

By Prophylaxis Type Analysis

Based on prophylaxis type, the market is classified into pre-exposure prophylaxis and post-exposure prophylaxis. The pre-exposure prophylaxis segment acquired a 40% revenue share in the market in 2022. Pre-exposure prophylaxis offers long-term protection, reducing the need for immediate post-exposure treatment for potential rabies exposure. This long-term protection can be cost-effective in the long run, considering the expenses associated with post-exposure prophylaxis.

By End User Analysis

Based on end user, the market is segmented into hospitals, veterinary clinics, and others. The veterinary clinics segment recorded a 20% revenue share in the market in 2022. A greater demand for veterinary services, such as rabies vaccination, has resulted from the global rise in the prevalence of pet ownership. Routine vaccination programs are integral to the preventive healthcare veterinary clinics provide to pets, including dogs and cats.



By Application Analysis

On the basis of application, the market is bifurcated into human and animal. The animal segment garnered a 30% revenue share in the market in 2022. Animals, particularly mammals, serve as the primary reservoirs of the rabies virus. Controlling rabies in animal populations is essential to reduce the risk of transmission to humans through bites or scratches.

By Product Type Analysis

By product type, the market is categorized into chick embryo cells rabies vaccine, Vero cell rabies vaccine, human diploid cell vaccine, and others. The Vero cell rabies vaccine segment covered a 20% revenue share in the market in 2022. The Vero cell vaccine eliminates the use of nervous tissue in its production, addressing safety concerns associated with traditional nerve tissue-derived vaccines. Removing nervous tissue reduces the risk of adverse reactions, making the Vero cell vaccine a safer option for rabies prevention.

By Regional Analysis

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating 40% revenue share. North America's health authorities and veterinary services implement strategic vaccination programs targeting domestic and wildlife populations. Veterinary clinics and practices across North America actively participate in rabies prevention by providing pet vaccination services.

List of Key Companies Profiled

  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Serum Institute of India Pvt. Ltd. (Cyrus Poonawalla Group)
  • Elanco Animal Health, Inc.
  • Zoetis, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Bharat Biotech Ltd.
  • Sanofi S.A.
  • Virbac

Market Report Segmentation

By Prophylaxis Type
  • Post-exposure Prophylaxis
  • Pre-exposure prophylaxis
By End User
  • Hospitals
  • Veterinary Clinics
  • Others
By Application
  • Human
  • Animal
By Product Type
  • Chick Embryo Cells Rabies Vaccine
  • Human Diploid Cell Vaccine
  • Vero cell rabies vaccine
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Rabies Vaccine Market, by Prophylaxis Type
1.4.2 Global Rabies Vaccine Market, by End User
1.4.3 Global Rabies Vaccine Market, by Application
1.4.4 Global Rabies Vaccine Market, by Product Type
1.4.5 Global Rabies Vaccine Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Opportunities
3.2.3 Market Restraints
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Global Rabies Vaccine Market by Prophylaxis Type
4.1 Global Post-exposure Prophylaxis Market by Region
4.2 Global Pre-exposure prophylaxis Market by Region
Chapter 5. Global Rabies Vaccine Market by End User
5.1 Global Hospitals Market by Region
5.2 Global Veterinary Clinics Market by Region
5.3 Global Others Market by Region
Chapter 6. Global Rabies Vaccine Market by Application
6.1 Global Human Market by Region
6.2 Global Animal Market by Region
Chapter 7. Global Rabies Vaccine Market by Product Type
7.1 Global Chick Embryo Cells Rabies Vaccine Market by Region
7.2 Global Human Diploid Cell Vaccine Market by Region
7.3 Global Vero Cell Rabies Vaccine Market by Region
7.4 Global Others Market by Region
Chapter 8. Global Rabies Vaccine Market by Region
8.1 North America Rabies Vaccine Market
8.1.1 North America Rabies Vaccine Market by Prophylaxis Type
8.1.1.1 North America Post-exposure Prophylaxis Market by Region
8.1.1.2 North America Pre-exposure prophylaxis Market by Region
8.1.2 North America Rabies Vaccine Market by End User
8.1.2.1 North America Hospitals Market by Country
8.1.2.2 North America Veterinary Clinics Market by Country
8.1.2.3 North America Others Market by Country
8.1.3 North America Rabies Vaccine Market by Application
8.1.3.1 North America Human Market by Country
8.1.3.2 North America Animal Market by Country
8.1.4 North America Rabies Vaccine Market by Product Type
8.1.4.1 North America Chick Embryo Cells Rabies Vaccine Market by Country
8.1.4.2 North America Human Diploid Cell Vaccine Market by Country
8.1.4.3 North America Vero Cell Rabies Vaccine Market by Country
8.1.4.4 North America Others Market by Country
8.1.5 North America Rabies Vaccine Market by Country
8.1.5.1 US Rabies Vaccine Market
8.1.5.1.1 US Rabies Vaccine Market by Prophylaxis Type
8.1.5.1.2 US Rabies Vaccine Market by End User
8.1.5.1.3 US Rabies Vaccine Market by Application
8.1.5.1.4 US Rabies Vaccine Market by Product Type
8.1.5.2 Canada Rabies Vaccine Market
8.1.5.2.1 Canada Rabies Vaccine Market by Prophylaxis Type
8.1.5.2.2 Canada Rabies Vaccine Market by End User
8.1.5.2.3 Canada Rabies Vaccine Market by Application
8.1.5.2.4 Canada Rabies Vaccine Market by Product Type
8.1.5.3 Mexico Rabies Vaccine Market
8.1.5.3.1 Mexico Rabies Vaccine Market by Prophylaxis Type
8.1.5.3.2 Mexico Rabies Vaccine Market by End User
8.1.5.3.3 Mexico Rabies Vaccine Market by Application
8.1.5.3.4 Mexico Rabies Vaccine Market by Product Type
8.1.5.4 Rest of North America Rabies Vaccine Market
8.1.5.4.1 Rest of North America Rabies Vaccine Market by Prophylaxis Type
8.1.5.4.2 Rest of North America Rabies Vaccine Market by End User
8.1.5.4.3 Rest of North America Rabies Vaccine Market by Application
8.1.5.4.4 Rest of North America Rabies Vaccine Market by Product Type
8.2 Europe Rabies Vaccine Market
8.2.1 Europe Rabies Vaccine Market by Prophylaxis Type
8.2.1.1 Europe Post-exposure Prophylaxis Market by Country
8.2.1.2 Europe Pre-exposure prophylaxis Market by Country
8.2.2 Europe Rabies Vaccine Market by End User
8.2.2.1 Europe Hospitals Market by Country
8.2.2.2 Europe Veterinary Clinics Market by Country
8.2.2.3 Europe Others Market by Country
8.2.3 Europe Rabies Vaccine Market by Application
8.2.3.1 Europe Human Market by Country
8.2.3.2 Europe Animal Market by Country
8.2.4 Europe Rabies Vaccine Market by Product Type
8.2.4.1 Europe Chick Embryo Cells Rabies Vaccine Market by Country
8.2.4.2 Europe Human Diploid Cell Vaccine Market by Country
8.2.4.3 Europe Vero Cell Rabies Vaccine Market by Country
8.2.4.4 Europe Others Market by Country
8.2.5 Europe Rabies Vaccine Market by Country
8.2.5.1 Germany Rabies Vaccine Market
8.2.5.1.1 Germany Rabies Vaccine Market by Prophylaxis Type
8.2.5.1.2 Germany Rabies Vaccine Market by End User
8.2.5.1.3 Germany Rabies Vaccine Market by Application
8.2.5.1.4 Germany Rabies Vaccine Market by Product Type
8.2.5.2 UK Rabies Vaccine Market
8.2.5.2.1 UK Rabies Vaccine Market by Prophylaxis Type
8.2.5.2.2 UK Rabies Vaccine Market by End User
8.2.5.2.3 UK Rabies Vaccine Market by Application
8.2.5.2.4 UK Rabies Vaccine Market by Product Type
8.2.5.3 France Rabies Vaccine Market
8.2.5.3.1 France Rabies Vaccine Market by Prophylaxis Type
8.2.5.3.2 France Rabies Vaccine Market by End User
8.2.5.3.3 France Rabies Vaccine Market by Application
8.2.5.3.4 France Rabies Vaccine Market by Product Type
8.2.5.4 Russia Rabies Vaccine Market
8.2.5.4.1 Russia Rabies Vaccine Market by Prophylaxis Type
8.2.5.4.2 Russia Rabies Vaccine Market by End User
8.2.5.4.3 Russia Rabies Vaccine Market by Application
8.2.5.4.4 Russia Rabies Vaccine Market by Product Type
8.2.5.5 Spain Rabies Vaccine Market
8.2.5.5.1 Spain Rabies Vaccine Market by Prophylaxis Type
8.2.5.5.2 Spain Rabies Vaccine Market by End User
8.2.5.5.3 Spain Rabies Vaccine Market by Application
8.2.5.5.4 Spain Rabies Vaccine Market by Product Type
8.2.5.6 Italy Rabies Vaccine Market
8.2.5.6.1 Italy Rabies Vaccine Market by Prophylaxis Type
8.2.5.6.2 Italy Rabies Vaccine Market by End User
8.2.5.6.3 Italy Rabies Vaccine Market by Application
8.2.5.6.4 Italy Rabies Vaccine Market by Product Type
8.2.5.7 Rest of Europe Rabies Vaccine Market
8.2.5.7.1 Rest of Europe Rabies Vaccine Market by Prophylaxis Type
8.2.5.7.2 Rest of Europe Rabies Vaccine Market by End User
8.2.5.7.3 Rest of Europe Rabies Vaccine Market by Application
8.2.5.7.4 Rest of Europe Rabies Vaccine Market by Product Type
8.3 Asia Pacific Rabies Vaccine Market
8.3.1 Asia Pacific Rabies Vaccine Market by Prophylaxis Type
8.3.1.1 Asia Pacific Post-exposure Prophylaxis Market by Country
8.3.1.2 Asia Pacific Pre-exposure prophylaxis Market by Country
8.3.2 Asia Pacific Rabies Vaccine Market by End User
8.3.2.1 Asia Pacific Hospitals Market by Country
8.3.2.2 Asia Pacific Veterinary Clinics Market by Country
8.3.2.3 Asia Pacific Others Market by Country
8.3.3 Asia Pacific Rabies Vaccine Market by Application
8.3.3.1 Asia Pacific Human Market by Country
8.3.3.2 Asia Pacific Animal Market by Country
8.3.4 Asia Pacific Rabies Vaccine Market by Product Type
8.3.4.1 Asia Pacific Chick Embryo Cells Rabies Vaccine Market by Country
8.3.4.2 Asia Pacific Human Diploid Cell Vaccine Market by Country
8.3.4.3 Asia Pacific Vero Cell Rabies Vaccine Market by Country
8.3.4.4 Asia Pacific Others Market by Country
8.3.5 Asia Pacific Rabies Vaccine Market by Country
8.3.5.1 China Rabies Vaccine Market
8.3.5.1.1 China Rabies Vaccine Market by Prophylaxis Type
8.3.5.1.2 China Rabies Vaccine Market by End User
8.3.5.1.3 China Rabies Vaccine Market by Application
8.3.5.1.4 China Rabies Vaccine Market by Product Type
8.3.5.2 Japan Rabies Vaccine Market
8.3.5.2.1 Japan Rabies Vaccine Market by Prophylaxis Type
8.3.5.2.2 Japan Rabies Vaccine Market by End User
8.3.5.2.3 Japan Rabies Vaccine Market by Application
8.3.5.2.4 Japan Rabies Vaccine Market by Product Type
8.3.5.3 India Rabies Vaccine Market
8.3.5.3.1 India Rabies Vaccine Market by Prophylaxis Type
8.3.5.3.2 India Rabies Vaccine Market by End User
8.3.5.3.3 India Rabies Vaccine Market by Application
8.3.5.3.4 India Rabies Vaccine Market by Product Type
8.3.5.4 South Korea Rabies Vaccine Market
8.3.5.4.1 South Korea Rabies Vaccine Market by Prophylaxis Type
8.3.5.4.2 South Korea Rabies Vaccine Market by End User
8.3.5.4.3 South Korea Rabies Vaccine Market by Application
8.3.5.4.4 South Korea Rabies Vaccine Market by Product Type
8.3.5.5 Singapore Rabies Vaccine Market
8.3.5.5.1 Singapore Rabies Vaccine Market by Prophylaxis Type
8.3.5.5.2 Singapore Rabies Vaccine Market by End User
8.3.5.5.3 Singapore Rabies Vaccine Market by Application
8.3.5.5.4 Singapore Rabies Vaccine Market by Product Type
8.3.5.6 Malaysia Rabies Vaccine Market
8.3.5.6.1 Malaysia Rabies Vaccine Market by Prophylaxis Type
8.3.5.6.2 Malaysia Rabies Vaccine Market by End User
8.3.5.6.3 Malaysia Rabies Vaccine Market by Application
8.3.5.6.4 Malaysia Rabies Vaccine Market by Product Type
8.3.5.7 Rest of Asia Pacific Rabies Vaccine Market
8.3.5.7.1 Rest of Asia Pacific Rabies Vaccine Market by Prophylaxis Type
8.3.5.7.2 Rest of Asia Pacific Rabies Vaccine Market by End User
8.3.5.7.3 Rest of Asia Pacific Rabies Vaccine Market by Application
8.3.5.7.4 Rest of Asia Pacific Rabies Vaccine Market by Product Type
8.4 LAMEA Rabies Vaccine Market
8.4.1 LAMEA Rabies Vaccine Market by Prophylaxis Type
8.4.1.1 LAMEA Post-exposure Prophylaxis Market by Country
8.4.1.2 LAMEA Pre-exposure prophylaxis Market by Country
8.4.2 LAMEA Rabies Vaccine Market by End User
8.4.2.1 LAMEA Hospitals Market by Country
8.4.2.2 LAMEA Veterinary Clinics Market by Country
8.4.2.3 LAMEA Others Market by Country
8.4.3 LAMEA Rabies Vaccine Market by Application
8.4.3.1 LAMEA Human Market by Country
8.4.3.2 LAMEA Animal Market by Country
8.4.4 LAMEA Rabies Vaccine Market by Product Type
8.4.4.1 LAMEA Chick Embryo Cells Rabies Vaccine Market by Country
8.4.4.2 LAMEA Human Diploid Cell Vaccine Market by Country
8.4.4.3 LAMEA Vero Cell Rabies Vaccine Market by Country
8.4.4.4 LAMEA Others Market by Country
8.4.5 LAMEA Rabies Vaccine Market by Country
8.4.5.1 Brazil Rabies Vaccine Market
8.4.5.1.1 Brazil Rabies Vaccine Market by Prophylaxis Type
8.4.5.1.2 Brazil Rabies Vaccine Market by End User
8.4.5.1.3 Brazil Rabies Vaccine Market by Application
8.4.5.1.4 Brazil Rabies Vaccine Market by Product Type
8.4.5.2 Argentina Rabies Vaccine Market
8.4.5.2.1 Argentina Rabies Vaccine Market by Prophylaxis Type
8.4.5.2.2 Argentina Rabies Vaccine Market by End User
8.4.5.2.3 Argentina Rabies Vaccine Market by Application
8.4.5.2.4 Argentina Rabies Vaccine Market by Product Type
8.4.5.3 UAE Rabies Vaccine Market
8.4.5.3.1 UAE Rabies Vaccine Market by Prophylaxis Type
8.4.5.3.2 UAE Rabies Vaccine Market by End User
8.4.5.3.3 UAE Rabies Vaccine Market by Application
8.4.5.3.4 UAE Rabies Vaccine Market by Product Type
8.4.5.4 Saudi Arabia Rabies Vaccine Market
8.4.5.4.1 Saudi Arabia Rabies Vaccine Market by Prophylaxis Type
8.4.5.4.2 Saudi Arabia Rabies Vaccine Market by End User
8.4.5.4.3 Saudi Arabia Rabies Vaccine Market by Application
8.4.5.4.4 Saudi Arabia Rabies Vaccine Market by Product Type
8.4.5.5 South Africa Rabies Vaccine Market
8.4.5.5.1 South Africa Rabies Vaccine Market by Prophylaxis Type
8.4.5.5.2 South Africa Rabies Vaccine Market by End User
8.4.5.5.3 South Africa Rabies Vaccine Market by Application
8.4.5.5.4 South Africa Rabies Vaccine Market by Product Type
8.4.5.6 Nigeria Rabies Vaccine Market
8.4.5.6.1 Nigeria Rabies Vaccine Market by Prophylaxis Type
8.4.5.6.2 Nigeria Rabies Vaccine Market by End User
8.4.5.6.3 Nigeria Rabies Vaccine Market by Application
8.4.5.6.4 Nigeria Rabies Vaccine Market by Product Type
8.4.5.7 Rest of LAMEA Rabies Vaccine Market
8.4.5.7.1 Rest of LAMEA Rabies Vaccine Market by Prophylaxis Type
8.4.5.7.2 Rest of LAMEA Rabies Vaccine Market by End User
8.4.5.7.3 Rest of LAMEA Rabies Vaccine Market by Application
8.4.5.7.4 Rest of LAMEA Rabies Vaccine Market by Product Type
Chapter 9. Company Profiles
9.1 Cadila Pharmaceuticals Limited
9.1.1 Company Overview
9.1.2 Recent strategies and developments:
9.1.2.1 Product Launches and Product Expansions:
9.2 Bharat Biotech Ltd.
9.2.1 Company Overview
9.3 Serum Institute of India Pvt. Ltd. (Cyrus Poonawalla Group)
9.3.1 Company Overview
9.4 Boehringer Ingelheim International GmbH
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional & Segmental Analysis
9.4.4 Research & Development Expenses
9.4.5 SWOT Analysis
9.5 Elanco Animal Health, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional Analysis
9.5.4 Research & Development Expense
9.5.5 SWOT Analysis
9.6 Zoetis, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expense
9.6.5 SWOT Analysis
9.7 Merck & Co., Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 SWOT Analysis
9.8 Novartis AG
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Sanofi S.A.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.9.5 SWOT Analysis
9.10. Virbac
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 SWOT Analysis
Chapter 10. Winning imperative of Rabies Vaccine Market

Companies Mentioned

  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Serum Institute of India Pvt. Ltd. (Cyrus Poonawalla Group)
  • Elanco Animal Health, Inc.
  • Zoetis, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Bharat Biotech Ltd.
  • Sanofi S.A.
  • Virbac

Methodology

Loading
LOADING...